| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,
,
* Department of Medicine, Hollis Laboratory of Occupational and Environmental Health, Division of Environmental and Occupational Health Sciences, National Jewish Medical and Research Center, Denver, CO 80206;
Department of Medicine, Division of Pulmonary Science and Critical Care Medicine and
Departments of Preventive Medicine and Biometrics and
Immunology, University of Colorado Health Sciences Center, Denver, CO 80262; and
¶
Department of Occupational and Environmental Medicine, Interstitial Lung Disease Unit, Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, United Kingdom
A glutamic acid at residue 69(Glu69) in the HLA-DPB1 gene (Glu69) is associated with chronic beryllium disease (CBD) and possibly beryllium sensitization (BeS). This study tested the hypothesis that MHC class II polymorphisms are important in susceptibility to BeS and CBD and that the Glu69 variant is related to markers of disease severity. Genomic DNA was obtained from BeS (n = 50), CBD (n = 104), and beryllium-exposed nondiseased (Be-nondiseased) (n = 125) subjects. HLA-DPB1, -DRB1, and -DQB1 genotypes were determined by (sequence-specific primers) PCR. Disease severity was assessed by pulmonary function and exercise testing. A higher frequency of the DPB1 Glu69 gene was found in CBD and BeS compared with the Be-nondiseased subjects, with odds ratios of 10.1 for CBD vs Be-nondiseased and 9.5 for BeS vs Be-nondiseased. The majority of BeS and CBD subjects displayed non-0201 Glu69 alleles. Glu69 homozygosity was higher in the CBD subjects, while BeS subjects were intermediate and Be-nondiseased lowest. DRB1*01 and DQB1*05 phenotypes were reduced in CBD vs Be-nondiseased subjects, while DRB1*13 and DQB1*06 were associated with CBD in the absence of Glu69. Markers of disease severity, including a lower forced vital capacity, diffusion capacity for carbon monoxide, PaO2 at rest, maximum workload on exercise testing, and a higher arterial-alveolar gradient at rest, were associated with Glu69 homozygosity. We conclude that DPB1 Glu69 is a marker of sensitization and not specific for disease. Glu69 homozygosity acts as a functional marker associated with markers of CBD severity.
This article has been cited by other articles:
|
|
 |
|
  D. G. Mack, A. M. Lanham, B. E. Palmer, L. A. Maier, and A. P. Fontenot CD27 Expression on CD4+ T Cells Differentiates Effector from Regulatory T Cell Subsets in the Lung J. Immunol., June 1, 2009; 182(11): 7317 - 7324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Snyder, E. Demchuk, E. C McCanlies, C. R Schuler, K. Kreiss, M. E Andrew, B. L Frye, J. S Ensey, M. L Stanton, and A. Weston Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease J R Soc Interface, July 6, 2008; 5(24): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D C Christiani, A J Mehta, and C-L Yu Genetic susceptibility to occupational exposures Occup. Environ. Med., June 1, 2008; 65(6): 430 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Maier, J. W. Martyny, J. Liang, and M. D. Rossman Recent Chronic Beryllium Disease in Residents Surrounding a Beryllium Facility Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Jonth, L. Silveira, T. E. Fingerlin, H. Sato, J. C. Luby, K. I. Welsh, C. S. Rose, L. S. Newman, R. M. du Bois, L. A. Maier, et al. TGF-beta1 Variants in Chronic Beryllium Disease and Sarcoidosis J. Immunol., September 15, 2007; 179(6): 4255 - 4262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Fontenot, T. S. Keizer, M. McCleskey, D. G. Mack, R. Meza-Romero, J. Huan, D. M. Edwards, Y. K. Chou, A. A. Vandenbark, B. Scott, et al. Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells J. Immunol., September 15, 2006; 177(6): 3874 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Bill, D. G. Mack, M. T. Falta, L. A. Maier, A. K. Sullivan, F. G. Joslin, A. K. Martin, B. M. Freed, B. L. Kotzin, and A. P. Fontenot Beryllium Presentation to CD4+ T Cells Is Dependent on a Single Amino Acid Residue of the MHC Class II {beta}-Chain J. Immunol., November 15, 2005; 175(10): 7029 - 7037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Chou, D. M. Edwards, A. D. Weinberg, A. A. Vandenbark, B. L. Kotzin, A. P. Fontenot, and G. G. Burrows Activation Pathways Implicate Anti-HLA-DP and Anti-LFA-1 Antibodies as Lead Candidates for Intervention in Chronic Berylliosis J. Immunol., April 1, 2005; 174(7): 4316 - 4324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Newman, M. M. Mroz, R. Balkissoon, and L. A. Maier Beryllium Sensitization Progresses to Chronic Beryllium Disease: A Longitudinal Study of Disease Risk Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Sawyer, C. E. Parsons, A. P. Fontenot, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, and L. S. Newman Beryllium-Induced Tumor Necrosis Factor-{alpha} Production by CD4+ T Cells Is Mediated by HLA-DP Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
